3) Imatinib is a life saving drug for chronic myeloid leukemia. The poster child for successful targeted cancer treatment. It was introduced in 2001 at $32000 per year.
Price rose to >$100,000 by 2012. Lesson 1: Price of old drugs in USA increase markedly for no apparent reason
4) The price of imatinib reached $120,000 a year by the time the first generic came to the market in 2017.
But the cost stayed high until more than 4 generics came into the market. Lesson 2: We need adequate number of competing generics to have an effect on price @pritikrishtel
5) But even with multiple generics, the price was still very high.
Look at the huge difference from whole sale acquisition cost to average whole sale price. Massive.
6) Lesson 3: The price of a drug is being marked up a lot from when it leaves the manufacturer to when it reaches the patient. The supply chain benefits from a high price.
This is the same story as we have seen with insulin and many other drugs.
7) @costplusdrugs and other online pharmacies are now able to make the drug available at markedly low prices by cutting out rebates and fees that go to middlemen. I’m very glad about this. Kudos!
Lesson 4: Altruistic private companies can make a big difference.
8) @costplusdrugs and some other online pharmacies (like Scriptco) have made it cheaper to buy some drugs with cash than the copay that patients have to shell out with insurance. By negotiating for allow price for the manufacturer, eliminating middlemen, and efficient dispensing
9) @costplusdrugs in particular has had a huge impact in under one year! See my first tweet from earlier this year. They have >1000 drugs at prices lower than almost anywhere else. Particularly helpful for uninsured and underinsured patients.
“Professional knowledge has to be acquired the hard way. Without professional knowledge you can never have competence. And if you don’t have professional competence you cannot be a leader”. Sam Manekshaw, Chief of Indian Army 1969-73.
My slides and key takeaways from 2 days of intense discussion at the FDA/IMS meeting on drug development in myeloma. Applies to other cancers as well. #MedTwitter@FDAOncology@Myeloma_Society
1) 15 new drugs approved for myeloma in the last 20 years! Incredible.
2) 8 drugs approved first through the accelerated approval pathway. This enabled important drugs to become available to tens of thousands of patients with relapsed myeloma 2-3 years earlier than if we had waited for the full approval trial. @NorthTxMSG
3) With accelerated approval there is always a trade off between having active drugs available for patients with unmet need who have a life threatening illness versus the risk that some drugs without adequate clinical benefit or with risks slipping through (eg. Pano, melflufen)
1. Medicare should be able to negotiate at the time a new drug is first launched as they do in other developed countries — otherwise prices of new drugs will be frontloaded with a higher price to compensate.
I tweet on medicine, myeloma, cancer, healthcare policy, prescription drug costs, COVID, music, and more.
I don’t need Twitter to make an impact in my field. But I love the engagement and the opportunity to quickly disseminate information. Twitter makes it definitely easier for me to reach more people. I love it.
I’ve encountered trolls only after COVID. But 99.9% have been anonymous accounts. I just mute people who are rude and move on.
I haven’t blocked anyone so far (even after being on Twitter for 12 years). Let’s see if that changes.
At Mayo Clinic, we classify myeloma patients into one of 6 non-overlapping categories based on primary cytogenetic abnormalities that occur at the MGUS stage. #MedTwitter
Needs testing beyond just looking for prognostic markers 1/
Because primary cytogenetic abnormalities occur at the time of origin of MGUS, even if testing was not done at baseline, we can classify myeloma based on a subsequent study.
Thus, a t(4;14) first detected in relapsed myeloma implies presence from the very outset at MGUS stage.
In contrast, secondary cytogenetic abnormalities such as gain 1q, del 17p, del 13, can occur at any time in disease evolution. Further one or more of these secondary abnormalities can occur in each of the 6 main types of myeloma & change their clinical course @NatRevClinOncol 3/